Insider · CIK 0001802528
Fairmount Funds Management LLC
directorowner
Files at ORKA (Oruka Therapeutics, Inc.), CBIO (CRESCENT BIOPHARMA, INC.), VRDN (Viridian Therapeutics, Inc.\DE), SYRE (Spyre Therapeutics, Inc.), KRSA (Cyclerion Therapeutics, Inc.), JBIO (Jade Biosciences, Inc.), ZBIO (Zenas BioPharma, Inc.), APGE (Apogee Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | KRSA Cyclerion Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Tomas Kiselak | +48,445 | $0.00 | $0 | 48,445 | 32 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: By Fairmount Healthcare Fund II LP | -340,855 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: By Tomas Kiselak | -51,166 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: By Peter Harwin | -51,166 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Non-Voting Common Stockderivativeindirect: By Fairmount Healthcare Fund II LP | -6,743,321 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | -47,758 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | -10,370 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | -14,461 | - | - | 0 | 39 d ago |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | -7,657 | - | - | 0 | 39 d ago |
| Jun 23, 2025 | CBIO CRESCENT BIOPHARMA, INC. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | +9,023 | $0.00 | $0 | 9,023 | Jun 23, 2025 |
| Jun 17, 2025 | APGE Apogee Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 17, 2025 | APGE Apogee Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Tomas Kiselak | +14,461 | $0.00 | $0 | 14,461 | Jun 20, 2025 |
| Jun 10, 2025 | ZBIO Zenas BioPharma, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
| Jun 9, 2025 | VRDN Viridian Therapeutics, Inc.\DE | MOption exercise Common Stockindirect: Fairmount Healthcare Fund II LP | +1,600 | $7.80 | $12k | 3,447,413 | Jun 11, 2025 |
| Jun 10, 2025 | VRDN Viridian Therapeutics, Inc.\DE | MOption exercise Common Stockindirect: Fairmount Healthcare Fund II LP | +12,500 | $12.31 | $154k | 3,459,913 | Jun 11, 2025 |
| Jun 9, 2025 | VRDN Viridian Therapeutics, Inc.\DE | MOption exercise Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | -1,600 | $0.00 | $0 | 0 | Jun 11, 2025 |
| Jun 10, 2025 | VRDN Viridian Therapeutics, Inc.\DE | MOption exercise Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | -12,500 | $0.00 | $0 | 0 | Jun 11, 2025 |
| Jun 2, 2025 | ORKA Oruka Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By: Peter Harwin | +17,500 | $0.00 | $0 | 17,500 | Jun 3, 2025 |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Peter Harwin | +25,000 | $0.00 | $0 | 25,000 | Jun 2, 2025 |
| May 29, 2025 | SYRE Spyre Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivativeindirect: By Tomas Kiselak | +25,000 | $0.00 | $0 | 25,000 | Jun 2, 2025 |
| Apr 29, 2025 | JBIO Jade Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +23,017 | $0.00 | $0 | 23,017 | May 1, 2025 |
| Nov 19, 2024 | ORKA Oruka Therapeutics, Inc. | MOption exercise Common Stockindirect: By Fairmount Healthcare Fund II L.P. | +160,000 | - | - | 798,614 | Nov 21, 2024 |
| Nov 19, 2024 | ORKA Oruka Therapeutics, Inc. | MOption exercise Series A Non-Voting Convertible Preferred Stockderivativeindirect: By Fairmount Healthcare Fund II L.P. | -160 | $0.00 | $0 | 0 | Nov 21, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.